AXSM:NSD-Axsome Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 77.02

Change

+1.09 (+1.44)%

Market Cap

USD 2.89B

Volume

0.25M

Average Target Price

USD 160.57 (+108.48%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+5.05 (+1.92%)

USD68.72B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

+16.60 (+2.98%)

USD60.13B 21.90 16.92
SGEN Seattle Genetics, Inc

+5.52 (+3.08%)

USD31.19B N/A N/A
MRNA Moderna, Inc

+4.30 (+6.60%)

USD26.58B N/A N/A
RPRX Royalty Pharma plc

-0.16 (-0.40%)

USD25.36B 35.72 9.73
ALXN Alexion Pharmaceuticals, Inc

+2.41 (+2.15%)

USD24.64B 30.43 27.52
BGNE BeiGene, Ltd

+5.83 (+2.11%)

USD24.64B N/A N/A
GMAB Genmab A/S

+1.03 (+2.94%)

USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

+0.06 (+0.07%)

USD19.69B N/A N/A
INCY Incyte Corporation

+1.48 (+1.74%)

USD18.80B 47.64 35.20

ETFs Containing AXSM

Symbol Name Weight Mer Price(Change) Market Cap
DWAQ Invesco DWA NASDAQ Moment.. 0.00 % 0.60 %

N/A

USD0.05B
DWAS Invesco DWA SmallCap Mome.. 0.00 % 0.60 %

+1.65 (+2.93%)

USD0.23B
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

+0.45 (+3.15%)

USD0.02B
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

+4.93 (+3.84%)

USD0.52B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.48% 33% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.48% 33% F 32% F
Trailing 12 Months  
Capital Gain 248.66% 90% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 248.66% 90% A- 95% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 253.01% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 253.01% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 576.94% N/A N/A N/A N/A
Risk Adjusted Return 43.85% N/A N/A N/A N/A
Market Capitalization 2.89B 88% B+ 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 19.12 6% F 6% F
Price / Cash Flow Ratio -62.38 96% A 94% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -106.15% 28% F 12% F
Return on Invested Capital -64.99% 48% F 15% F
Return on Assets -47.56% 19% F 6% F
Debt to Equity Ratio 9.70% 65% D 75% C
Technical Ratios  
Short Ratio 10.67 20% F 11% F
Short Percent 13.23% 21% F 16% F
Beta 2.82 5% F 4% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector